Quick summary
Goldenseal (Hydrastis canadensis) is a medicinal plant under ongoing research for potential therapeutic applications. Current human clinical evidence is limited. A single case report suggests it may act as a CYP2D6 inhibitor to prolong drug exposure when used in combination therapy for obsessive-compulsive disorder (OCD), but controlled clinical trials are lacking. Goldenseal contains alkaloids including berberine, a compound more extensively studied for various health effects in other contexts. At this time, there is no definitive high-quality clinical trial evidence supporting specific health benefits of Goldenseal itself.
What is it
Goldenseal is a perennial herb native to North America known for its yellow roots and rhizomes. It belongs to the Ranunculaceae family and has been used traditionally as a medicinal plant. The root and rhizome contain a variety of alkaloids, notably berberine, which contribute to its pharmacological properties.
Traditional uses
Historically, Goldenseal has been employed in traditional herbal medicine as a remedy for infections, digestive issues, and inflammation. It has been used topically and internally for conditions such as wounds, respiratory problems, and urinary tract complaints. These uses are based largely on ethnomedical knowledge rather than robust clinical data.
Active compounds
- Berberine: An isoquinoline alkaloid investigated for antimicrobial, anti-inflammatory, and metabolic effects.
- Hydrastine: Another alkaloid contributing to Goldenseal’s bitter taste and pharmacologic actions.
- Other alkaloids: Such as canadine, which may influence various biological activities.
Potential benefits with evidence levels
- Adjunct in glutamatergic regimen for treatment-intolerant OCD: Evidence level – a single case report (n=1) without controlled trials. A 16-year-old male with severe OCD who could not tolerate standard serotonergic agents showed marked symptom improvement after adding Goldenseal root extract (600 mg/day), possibly by inhibiting CYP2D6 and thereby prolonging exposure to dextromethorphan. No adverse effects were observed during a two-month follow-up. Controlled studies are needed to confirm efficacy and safety. [Cheung 2026]
- Antibacterial and tissue-protective effects in urinary tract infections (related herbal activity): Evidence level – preclinical and ethnomedical data. Alkaloid-rich medicinal plants such as Goldenseal, containing berberine, have shown antibacterial properties and potential tissue protection in experimental models. However, there is no direct clinical evidence of Goldenseal’s effectiveness in treating urinary tract infections in humans. [Heger et al. 2025]
Side effects
There is insufficient clinical data regarding specific adverse effects of Goldenseal. One reported clinical case did not observe any side effects over two months of use. Preclinical data suggest the potential for herb-drug interactions through cytochrome P450 enzyme modulation, particularly CYP2D6 inhibition. No serious adverse events directly attributed to Goldenseal have been documented in available data. Definitive safety profiles require further clinical evaluation.
Drug interactions
Goldenseal contains components that may inhibit CYP2D6, an enzyme responsible for metabolizing many drugs. This action could increase blood levels of co-administered medications metabolized by CYP2D6, such as dextromethorphan, potentially altering their effects or toxicity. Caution is advised when using Goldenseal alongside drugs processed by this enzyme system due to possible herb-drug interactions.
Who should avoid it
- Individuals taking multiple medications metabolized by cytochrome P450 enzymes, especially CYP2D6, should exercise caution or consult healthcare providers before use due to interaction risk.
- Pregnant and breastfeeding women are advised to avoid Goldenseal as there is no direct evidence regarding its safety in these populations.
- Persons with hypersensitivity to plants of the Ranunculaceae family or known Goldenseal constituents should avoid use.
Evidence limitations
Human clinical evidence for Goldenseal is very limited, primarily consisting of a single case report without any controlled trials. Most claims of benefit derive from related compounds like berberine studied independently or from preclinical and ethnobotanical data rather than direct clinical investigation of Goldenseal itself. Safety and herb-drug interaction profiles have not been extensively characterized in large human populations. Well-designed randomized controlled trials are needed to establish clear efficacy, safety, dosing guidelines, and interaction potential.
References
- Cheung N. Marked Improvement in Treatment-Intolerant Obsessive-Compulsive Disorder in an Adolescent Using a Glutamatergic Regimen With Dextromethorphan, Piracetam, and Goldenseal Root. 2026. doi:10.7759/cureus.104617
- Heger PW, Meinert I, Nick P, Riedl P, Heinrich M, Straub M. Sustainable spectrofluorimetric determination of berberine in dietary supplements. 2025. doi:10.1080/13880209.2025.2457328
- Patel D et al. Improving the rigor and utility of botanical toxicity studies: Recommended resources. 2023. doi:10.1016/j.yrtph.2023.105471
- Husain I et al. Screening of medicinal plants for possible herb-drug interactions through modulating nuclear receptors, drug-metabolizing enzymes and transporters. 2023. doi:10.1016/j.jep.2022.115822
- Babos MB et al. Herb-Drug Interactions: Worlds Intersect with the Patient at the Center. 2021. doi:10.3390/medicines8080044
- Grimstein M, Huang SM. A regulatory science viewpoint on botanical-drug interactions. 2018. doi:10.1016/j.jfda.2018.01.013
Last reviewed
April 2024
Disclaimer: This information is provided for educational purposes only and is not intended to substitute professional medical advice, diagnosis, or treatment. Always consult a healthcare professional before starting any new herbal or dietary supplement, especially if you have underlying health conditions or are taking other medications.